Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

ELEVATE-RR and ALPINE Trials in Relapsed CLL

December 8th 2021

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

BTK Inhibitors in the Management of CLL

December 8th 2021

Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Overview of Marginal Zone Lymphoma and Frontline Treatment

December 6th 2021

Tycel Jovelle Phillips, MD, and Alexey Danilov, MD, share insights on common signs and symptoms of marginal zone lymphoma and approaching initial therapy.

Novel Agents and Ongoing Trials in R/R Follicular Lymphoma

December 6th 2021

Dr Tycel Jovelle Phillips reviews key ongoing trials in relapsed/refractory follicular lymphoma.

FDA Grants Priority Review to Luspatercept-aamt for Non–Transfusion Dependent Beta Thalassemia

December 3rd 2021

The FDA has granted priority review to the supplemental biologics license application for luspatercept-aamt for the treatment of anemia in adults with non–transfusion dependent β-thalassemia.

FDA Approves Rituximab/Chemo for Pediatric Cancer Indications

December 3rd 2021

The FDA has approved rituximab plus chemotherapy for pediatric patients with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia.

Brexucabtagene Autoleucel Expands Treatment Possibilities in ALL

December 3rd 2021

Bijal Shah, MD, MS, discussed the results of the ZUMA-3 trial and how this approval will enhance the treatment of patients with relapsed or refractory B-cell precursor ALL.

FDA Places Partial Clinical Hold on KO-539 Trial in Relapsed/Refractory AML

December 2nd 2021

The FDA has placed a partial clinical hold on the phase 1b KOMET-001 trial, which is examining KO-539 in patients with relapsed or refractory acute myeloid leukemia.

Dr. Chen on Risk Factors for Developing cGVHD

December 1st 2021

Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.

Dr. Neumann on Tapering Steroids in cGVHD

December 1st 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Role of Tazemetostat and Selecting Appropriate Therapies in R/R FL

November 29th 2021

Expert hematologist-oncologists examine the use of tazemetostat based on a phase 2 trial for relapsed/refractory follicular lymphoma and consider clinical implications.

CHRONOS-1 and CHRONOS-3 Trials in R/R FL and Clinical Implications

November 29th 2021

Dr Alexey Danilov reviews the 2-year follow-up of the phase 2 CHRONOS-1 study evaluating the use of copanlisib monotherapy in relapsed/refractory follicular lymphoma.

Incorporating Mutational Panel Testing Remains Crucial in MDS

November 24th 2021

David Sallman, MD, discusses incorporating mutational testing of patients with myelodysplastic syndrome into clinical practice, and strategies that can be utilized to treat this population.

Enasidenib/Azacitidine Combo Shows Early, Promising Activity in IDH2-Mutant AML

November 23rd 2021

The combination of enasidenib plus azacitidine was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia.

FDA Grants Priority Review to Beti-Cel for β-thalassemia Requiring Transfusions

November 22nd 2021

The FDA has granted a priority review designation to a biologics license application for betibeglogene autotemcel for the treatment of adult, adolescent, and pediatric patients with β-thalassemia across all genotypes who require regular red blood cell transfusions.

Treatment Landscape Shifts Away From Chemotherapy Toward Targeted Approaches in ALL

November 22nd 2021

Novel approaches with highly active, minimally toxic agents are needed to improve upon traditional chemotherapy and possibly eliminate chemotherapy altogether in the treatment of patients with acute lymphoblastic leukemia.

Variable Chronic GVHD Presentations Stress the Need for Close Symptom Monitoring

November 22nd 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses the variability in cGVHD presentation, key symptoms of the disease in patients with cancer, and how the field is navigating between available therapies.

Treatment Options for Follicular Lymphoma: Second Line and Beyond

November 22nd 2021

Tycel Jovelle Phillps, MD, shares second-line treatment approaches for the management of follicular lymphoma and examines the use of PI3K inhibitors.

Overview of Follicular Lymphoma and Frontline Treatment

November 22nd 2021

Alexey Danilov, MD, and Tycel Jovelle Phillips, MD, provide insight on common signs and symptoms of follicular lymphoma (FL) and factors to consider when selecting first-line therapy.

mRNA COVID-19 Vaccines May Decrease Efficacy in Lymphoid Malignancies

November 19th 2021

Patients with lymphoid malignancies, especially those who have received recent anti-CD20 antibody therapy, have reduced humoral responses to the mRNA COVID-19 vaccines, and as such, should continue to take precautionary measures against COVID-19 infection irrespective of vaccination status.